Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ERIC 2018 | Let me introduce you to ERIC: the European Research Initiative on CLL

Paolo Ghia • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

The European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) is an important organization, working to support research and patient care in the CLL space. Here, current ERIC President, Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, Milan, Italy, discusses the main aims and initiatives of ERIC with us from the ERIC International Meeting 2018, held in Barcelona, Spain.

More from Paolo Ghia

Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease 19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Arnon Kater et al. • 25 Apr 2025
A study investigating the efficacy of CAR-T therapy in Richter’s transformation 1:52
A study investigating the efficacy of CAR-T therapy in Richter’s transformation
Paolo Ghia • 27 Sep 2024
A study investigating outcomes for a rare subgroup of CLL with CNS involvement 2:17
A study investigating outcomes for a rare subgroup of CLL with CNS involvement
Paolo Ghia • 27 Sep 2024
The future of CLL treatment: aiming for long-lasting remission 1:42
The future of CLL treatment: aiming for long-lasting remission
Paolo Ghia • 27 Sep 2024

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals